Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination therapy for non‑small cell lung cancer. GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib acts on fibrotic and oncogenic pathways, providing therapeutic benefit in several serious lung conditions. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition when used with other agents.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Elevated liver enzymes: mild increase in hepatic transaminases. - Vomiting: occasional expulsion of stomach contents.

Serious or Rare Side Effects: - Severe liver injury: signs of hepatitis or jaundice. - Major bleeding: gastrointestinal or intracranial hemorrhage. - Cardiovascular events: myocardial infarction or stroke. - Severe infections: opportunistic or bacterial infections. - Gastrointestinal perforation: rare but life‑threatening ulceration.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor key parameters. - Monitor liver function: baseline and periodic testing is recommended. - Assess cardiovascular risk: use caution in patients with ischemic heart disease. - Avoid in severe hepatic impairment: contraindicated in marked liver dysfunction. - Use with caution in patients receiving anticoagulants: increased bleeding risk. - Pregnancy and lactation: safety not established; discuss risks with prescriber. - Store at room temperature: keep in original container, protect from moisture and light.

Nintedanib may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase nintedanib exposure. - Anticoagulants: heightened bleeding risk. - P‑gp inhibitors: increased plasma levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may reduce efficacy. - Antifungals (e.g., fluconazole): may require dose adjustment. - Diuretics: monitor for dehydration and renal function.